Latest Research
All publications from the Cancer3.AI database, newest first.
The ASH HematOmics Program supports integrative analysis of genomic and clinical data in hematologic diseases.
Lu C, et al
Researchers developed the ASH HematOmics Program (ASHOP), a free, open-access web platform designed to integrate and share genomic, transcriptomic, and clinical data for blood cancers. The platform encompasses data from 5,960 patients with conditions including acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndromes, and chronic lymphocytic leukemia, making it the first dedicated data integration resource for hematologic diseases. ASHOP allows clinicians and scientists to explore gene mutations, gene fusions, expression patterns, and patient outcomes through interactive visualizations such as mutation landscape plots and dimensionality-reduction maps. The platform demonstrated its utility through four real-world use cases, including identifying distinct subtypes of DUX4-rearranged leukemia with different patient outcomes and characterizing HOX gene expression patterns in acute myeloid leukemia. By enabling precise, user-driven correlation of molecular features with clinical outcomes, ASHOP has the potential to accelerate discovery of new prognostic markers and guide more personalized treatment decisions for blood cancer patients.
Blood
Source →Advanced Mature B-Cell Non-Hodgkin Lymphoma: Rituximab Works; However, Supportive Care Remains the Real Challenge.
Peyam S, et al
A study published in the Indian Journal of Pediatrics examined the outcomes of children diagnosed with advanced mature B-cell Non-Hodgkin Lymphoma (NHL), a fast-growing blood cancer that primarily affects lymph nodes and can spread rapidly in pediatric patients. The research evaluated the effectiveness of rituximab, a targeted antibody therapy, as part of the treatment regimen for this aggressive cancer type. Findings indicated that rituximab demonstrates meaningful clinical benefit in this patient population, contributing to improved disease control in advanced-stage cases. However, the study highlighted that supportive care — encompassing management of infections, treatment toxicities, and complications — continues to pose a significant challenge that can limit overall treatment success. These results underscore the importance of not only advancing targeted therapies but also strengthening the infrastructure for intensive supportive care in pediatric oncology settings, particularly in resource-limited environments such as those found in India. Clinicians are urged to address supportive care gaps alongside the adoption of rituximab-based protocols to optimize survival outcomes for young patients with this disease.
Indian journal of pediatrics
Source →Sanguinarine Induces ROS-Mediated Mitochondrial Dysfunction and Inhibits AKT/GSK3 Signaling to Potentiate Apoptotic Effects in Cutaneous T-Cell Lymphoma.
Kuttikrishnan S, et al
Researchers investigated the anticancer potential of sanguinarine (SNG), a natural plant-derived alkaloid, against cutaneous T-cell lymphoma (CTCL), a rare and difficult-to-treat skin cancer with few durable therapies. Using CTCL cell lines, the team demonstrated that SNG potently reduced cancer cell survival at low concentrations (IC50 below 5 micromolar) by triggering a cascade of oxidative stress, mitochondrial damage, and programmed cell death known as apoptosis. The compound was shown to increase harmful reactive oxygen species, deplete the antioxidant glutathione, disrupt mitochondrial membrane integrity, and suppress a key cancer survival signaling pathway called PI3K/AKT/GSK3/mTOR, while simultaneously downregulating proteins that normally protect cancer cells from dying. Notably, when combined with the approved cancer drug bortezomib, SNG produced synergistic anticancer effects, suggesting enhanced therapeutic potential beyond monotherapy. Computational modeling, including molecular docking and dynamics simulations, identified AKT and Bcl-2 proteins as primary molecular targets of SNG, providing mechanistic support for the experimental findings. These results position sanguinarine as a promising novel candidate for CTCL treatment, with the authors calling for further preclinical studies to advance its development.
Phytotherapy research : PTR
Source →Epstein-Barr virus (EBV) -related Hodgkin lymphoma in a 1-year-old child with DiGeorge syndrome.
Rao Z, et al
This report presents a rare case of Epstein-Barr virus (EBV)-associated Hodgkin lymphoma diagnosed in a 1-year-old child who also had DiGeorge syndrome, a genetic condition that causes significant immune system deficiency due to deletion of chromosome 22q11.2. Hodgkin lymphoma is extremely uncommon in infants under two years of age, and its occurrence alongside DiGeorge syndrome makes this case exceptionally rare in the medical literature. The underlying T-cell immunodeficiency characteristic of DiGeorge syndrome is believed to have created conditions allowing EBV infection to drive malignant lymphoma development at such an unusually young age. This case underscores the importance of vigilance for lymphoma in immunocompromised children, even in infancy, and highlights the role that impaired immune surveillance can play in cancer development. Clinicians caring for children with DiGeorge syndrome and similar primary immunodeficiencies should maintain heightened awareness of EBV-related malignancies as potential complications.
BMC pediatrics
Source →Sparassis crispa and a Bioactive Compound Therein, Ergosterol, Were Effective in Preventing Acetylcholinesterase Inhibition In Vitro and In Vivo.
Park CK, et al
Researchers investigated whether extracts from the edible mushroom Sparassis crispa and one of its key compounds, ergosterol, could help prevent cognitive decline associated with Alzheimer's disease by targeting two major disease mechanisms: cholinergic dysfunction and oxidative stress. Laboratory screening of multiple plant and mushroom extracts revealed that S. crispa exhibited strong inhibition of acetylcholinesterase (AChE), the enzyme whose overactivity degrades the memory-related neurotransmitter acetylcholine, and also showed significant antioxidant properties that protected brain cells from oxidative damage. Gas chromatography-mass spectrometry identified ergosterol as the primary bioactive compound responsible for these effects, and both the full extract and isolated ergosterol were then tested in mice with chemically induced cognitive impairment. Animals supplemented with S. crispa extract or ergosterol showed dose-dependent improvements in spatial working memory and aversive learning, reduced brain AChE activity, and lower levels of lipid peroxidation, a marker of oxidative brain damage, with no signs of liver toxicity. These findings are significant because they identify a natural, food-derived compound that simultaneously addresses two key pathological pathways in Alzheimer's disease, potentially offering a safer alternative or complement to current synthetic AChE inhibitor drugs. The study supports further development of S. crispa and ergosterol as functional food ingredients for the prevention or slowing of age-related cognitive decline.
Food science & nutrition
Source →